Challenges and limitations of targeting cancer stem cells and/or the tumour microenvironment


Submitted: 19 January 2012
Accepted: 16 March 2012
Published: 10 May 2012
Abstract Views: 4552
PDF: 1122
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The existence of cancer cells with stem cell properties (Cancer Stem Cells, CSCs) and their association with tumor resistance and relapse has led to the search for active compounds to eliminate these cells or modulate their stemness in the hope of curing cancer. So far, three classes of drugs that target cancer stemness (Stemness Modulator Drugs) have been identified: i) drugs that selectively eliminate CSCs (stem cell targeting drugs); ii) drugs that decrease stemness (stemness inhibitor drugs); and iii) drugs that promote stemness (stemness promoting drugs). In addition, microenvironment modulating drugs aimed at selectively targeting the stem cell niche are being investigated and may represent an important class of drug for cancer therapy. This article will briefly review the current use of these substances and discuss the potential outcomes, challenges and limitations of treatment modalities using these classes of drugs for cancer treatment. Finally, a modular tumor model will be proposed as a guide to integrate our knowledge on the biology of cancer stem cell with that of the tumor microenvironment to promote a more rational development of anticancer therapy.

Supporting Agencies

Swedish Research Council and the Karolinska Institute

Yakisich, J. S. (2012). Challenges and limitations of targeting cancer stem cells and/or the tumour microenvironment. Drugs and Therapy Studies, 2(1), e10. https://doi.org/10.4081/dts.2012.e10

Downloads

Download data is not yet available.

Citations